June 2020 // Communication

Updated: Mar 19

Synendos Therapeutics received a prestigious European grant (SME Instrument Phase I, TWO-BIRDS project ) that helped the company to head towards clinical trials. The European commission is now reporting about the results and the perspectives to treat post-traumatic stress disorder (PTSD) and other neuropsychiatric diseases. Read the full article here.



Recent Posts

See All

April 2021 // Communication

Lichtsteiner Foundation Testimonial Film about Synendos We are delighted to share the testimonial film created by the Lichtsteiner Foundation. Co-founder and CEO Andrea Chicca gives insights into entr

MARCH 2021 // Communication

We are excited to share a scientific publication about the beneficial effect of the prototype SERI WOBE437 in a clinically relevant mouse model of Multiple Sclerosis and transient spasticity. The arti